Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.

about

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.

Item

http://www.wikidata.org/entity/Q46574283

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.

@en

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.

@nl

type

Item

label

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.

@en

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.

@nl

prefLabel

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.

@en

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.

@nl

P1476

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy

@en

P2093

Christian A Kunder

http://www.w3.org/2001/XMLSchema#string

Christine L Egan

http://www.w3.org/2001/XMLSchema#string

Edward F Chan

http://www.w3.org/2001/XMLSchema#string

Roberto A Novoa

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Key roles for MYC, KIT and RET signaling in secondary angiosarcomas

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.

P304

1053-1056

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CUP.13024

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Julia Dai

Emily Y Chu

P577

2017-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28796396

http://www.w3.org/2001/XMLSchema#string